TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against aTyr Pharma for allegedly making false and misleading statements about its Phase 3 trial of Efzofitimod, potentially concealing the drug's true capabilities during the period of January 16-September 12, 2025.

Insights
TSLA   neutral

No specific positive or negative details provided in the article


ATYR   negative

The company is accused of making false statements about its drug trial, potentially misleading investors about Efzofitimod's capabilities, which suggests potential corporate misconduct and potential financial damages